BioSpace News Archive

Rapid Micro Biosystems, Inc. announced that, effective March 4, 2024, the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase 150,000 shares of the Company’s Class A common stock and 75,000 restricted stock units to a new employee under the Company’s 2023 Inducement Plan, as amended.

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2023 on Wednesday, March 13th after market hours.